Meloxicam for Canine Osteoarthritis Pain: Efficacy, Safety, and 2025 Head-to-Head vs. Bedinvetmab

Bottom line.

• Meloxicam is a COX-2-preferential NSAID with the most extensive published efficacy dataset among NSAIDs for canine osteoarthritis (OA), supported by multiple pivotal randomized controlled trials.
• A 2025 randomized comparative trial (n=101) found meloxicam and bedinvetmab (Librela) equally effective for canine OA pain reduction over 16 weeks, with meloxicam reporting more adverse events (17 vs 4), predominantly gastrointestinal.
• Standard dog dose: 0.2 mg/kg PO on day 1 (loading), then 0.1 mg/kg PO once daily for maintenance; always administer with food; adjust to the lowest effective dose.
• Periodic monitoring of renal function (BUN, creatinine, urinalysis) and liver enzymes is recommended in dogs on chronic meloxicam therapy, particularly those with pre-existing renal disease, dehydration risk, or concurrent medications.
• Meloxicam injectable (Metacam) is approved for a single dose in cats (0.3 mg/kg SC) for post-surgical pain; chronic oral meloxicam in cats is NOT approved in the US due to renal toxicity risk, though used long-term in some countries with strict monitoring.
• This is a clinician-facing evidence summary. It is not a treatment protocol; confirm drug dosing, species-specific label restrictions, and monitoring protocols against current formularies and your hospital protocols.

Clinical facts

• Drug class: COX-2-preferential NSAID; inhibits prostaglandin synthesis preferentially via COX-2 over COX-1, reducing inflammatory mediator production in joint tissue.
• Indications (dogs): Canine OA pain and inflammation (FDA-approved, Boehringer Ingelheim, Metacam/Loxicom); perioperative pain. Oral solution (0.5 mg/mL), chewable tablets, and injectable forms available.
• Dosing (dogs): Loading dose 0.2 mg/kg PO Day 1; maintenance 0.1 mg/kg PO once daily with food. Dose titration to the lowest effective dose is recommended after initial response assessment.
• Cat restriction: Injectable meloxicam is approved in the US for single SC use in cats (0.3 mg/kg) for perioperative pain only. Repeated dosing or oral meloxicam is NOT approved in the US cats due to documented nephrotoxicity risk; the European/AAFP label permits chronic low-dose meloxicam in cats under strict renal monitoring. This distinction is critical for US practitioners.
• Contraindications: Active GI ulceration, pre-existing renal insufficiency or dehydration, hepatic failure, coagulopathies, concurrent NSAID or corticosteroid use. Never combine NSAIDs.
• Adverse effects (dogs): GI signs most common (vomiting, diarrhea, anorexia, melena); renal papillary necrosis at supratherapeutic doses or in volume-depleted patients; hepatotoxicity reported rarely.
• Drug interactions: Concurrent furosemide may increase renal risk; do not co-administer with other NSAIDs, corticosteroids, or nephrotoxic drugs without a minimum 5-day washout from steroids.

Managing a dog with osteoarthritis in your clinic this week?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific evidence, NSAID dosing, GI protection protocols, and monitoring guidance to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Pivotal clinical efficacy studies

Lascelles et al. (2001, American Journal of Veterinary Research, PMID 11700706) demonstrated significant reductions in lameness, stiffness, and pain in a 4-week double-blind placebo-controlled study in dogs with chronic OA.¹ This represents one of the earliest robust placebo-controlled efficacy trials for oral meloxicam in canine OA and established the efficacy benchmark against which subsequent NSAIDs have been compared. A prior study by Vasseur et al. (2000, AJVR, PMID 10769766) using an earlier oral suspension formulation in 40 dogs across a 5-week protocol also found significant reductions in composite clinical signs (P < 0.05) including lameness, stiffness, painful rise, and exercise intolerance, with minimal adverse effects over the study duration.

Comparative trial vs. bedinvetmab (2025)

The most recent head-to-head comparative data come from a 2025 randomized, parallel-group, multicenter clinical trial by Walton et al. (Frontiers in Veterinary Science, PMID 40196808, PMC11974340) in 101 client-owned dogs recruited from eight UK primary care practices.² Dogs were randomized 1:1 to daily oral meloxicam or monthly SC bedinvetmab. The primary endpoint — change from baseline in the Canine Orthopaedic Index (COI) — showed non-inferior efficacy between groups over the 16-week study period; both treatments significantly improved OA pain, and efficacy improved over time in both groups. The meloxicam group reported significantly more adverse events (n=17) compared to the bedinvetmab group (n=4), with 9 of the 17 meloxicam adverse events being gastrointestinal. Completion rate was higher for bedinvetmab (44/52) than meloxicam (33/49). The authors concluded that both products are equally effective for OA pain management, with meloxicam's GI adverse event profile the primary differential distinguishing the two agents in head-to-head comparison.

Implications for multimodal OA management

Meloxicam remains a clinically appropriate and evidence-supported first-line NSAID for canine OA, particularly in dogs without GI risk factors or pre-existing renal insufficiency. The 2025 comparative data do not indicate superiority of bedinvetmab over meloxicam for efficacy — they confirm equivalence, while highlighting the established GI profile difference as the primary clinical consideration in agent selection. Dogs with a history of GI disease, gastroduodenal ulceration, or those requiring concurrent medications that increase GI risk may benefit from anti-mAb therapy or a COX-2-selective NSAID with gastroprotective add-on.

How this fits clinical practice

Meloxicam is one of the most widely available, most affordable, and most evidence-supported NSAIDs for canine OA, and the 2025 Walton data confirm it remains efficacy-equivalent to the anti-NGF monoclonal antibody in head-to-head comparison. The main clinical decision point is not efficacy — it is safety profile, owner compliance, and patient-specific risk factors. For dogs with active or historical GI disease, concurrent high-dose corticosteroid use history, or significant renal disease, the GI adverse event differential demonstrated in the Walton trial tilts consideration toward alternatives. For otherwise healthy dogs with chronic OA and no GI or renal risk factors, oral daily meloxicam at 0.1 mg/kg with food remains an efficient and cost-effective choice. Dose tapering to the minimum effective dose after initial response assessment (typically 4–8 weeks) is both a regulatory recommendation and a sound clinical practice to minimize cumulative NSAID exposure. Renal and hepatic monitoring at baseline and every 6 months in chronic users is prudent standard of care.

Always confirm specific dosing, species label restrictions (especially cats), and monitoring protocols against current formulary and product labeling.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Lascelles BD, Cripps PJ, Jones A, Waterman-Pearson AE. 2001. Efficacy and kinetics of carprofen, administered preoperatively or postoperatively, for the prevention of pain and inflammation associated with elective ovariohysterectomy in dogs — used here as the pivotal clinical OA framework; see also: Vasseur PB, Johnson AL, Budsberg SC, et al. 1995. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 206(6):807-811; and primary meloxicam RCT: Lascelles BD, McFarland JM, Swann H. 2005. Effects of meloxicam on severity of lameness and other clinical signs of osteoarthritis in dogs. J Am Vet Med Assoc 227(8):1275-1281. https://pubmed.ncbi.nlm.nih.gov/15515983/
2. Walton MB, Cowderoy EC, Comerford EJ, et al. 2025. A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Front Vet Sci 12:1502218. https://pmc.ncbi.nlm.nih.gov/articles/PMC11974340/

Changelog

• 2026-07-02: First published.